Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 299K | 0 | 0 | 0 | 0 |
| Gross Profit | 299K | 0 | 0 | 0 | 0 |
| Operating Income | -9M | 0 | 0 | 0 | 0 |
| EBITDA | -9M | -7M | -8M | -16M | -13M |
| Net Income | -29M | -13M | -6M | -6M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$3.67
-4.43% today
1Y Change
+6.42%
Window
Jun 23, 2025 → Jun 5, 2026
Coverage: 240 bars · Jun 23, 2025 → Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TAO Synergies Inc. (TAOX) is a Healthcare stock with a market cap of $20.00M and listed on NASDAQ. The stock last traded around $3.67 and up 6.4% across the available one-year price window (Jun 23, 2025 → Jun 5, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow -30.9% with operating margin -3259.2% and ROIC -40.6%. Valuation already assumes a fairly strong business story at price/sales 58.6. Stock Foundry combines TAOX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TAOX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TAOX Max Drawdown
-67.73%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TAOX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$12.6M
-126.3% YoY
Free Cash Flow
-$8.7M
+22.3% YoY
Revenue Growth
+0.0%
EPS Growth
+0.0%
Gross Margin
100.0%
Net Margin
-9609.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 299K | 0 | 0 | 0 | 0 |
| Gross Profit | 299K | 0 | 0 | 0 | 0 |
| Operating Income | -9M | 0 | 0 | 0 | 0 |
| EBITDA | -9M | -7M | -8M | -16M | -13M |
| Net Income | -29M | -13M | -6M | -6M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 18M | 29M | 37M | 34M |
| Total Assets | 26M | 18M | 31M | 39M | 36M |
| Total Liabilities | 4M | 11M | 6M | 3M | 2M |
| Shareholder Equity | 22M | 7M | 26M | 35M | 34M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -5M | -18M | -29M | -37M | -34M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
+22.3% YoY
Capital Expenditures
3K
+56.9% YoY
Free Cash Flow
9M
+22.3% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-3259.2%
Net Margin
-9609.2%
ROE
-182.5%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.